EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSTNIG00000009823
Gene Symbol: KCNQ5
2 Cross references
195 Possible Orthologues:

Potassium Voltage-Gated Channel, Kqt-Like Subfamily, Member 2a

Ensembl ID : ENSTNIG00000010870
Gene Symbol: KCNQ2A
2 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel, Shal-Related Subfamily, Member 3

Ensembl ID : ENSTNIG00000019424
Gene Symbol: KCND3
2 Cross references
192 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSTNIG00000019045
Gene Symbol: PGR
2 Cross references
193 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSTNIG00000012354
Gene Symbol: PTGDR2
3 Cross references
145 Possible Orthologues:

Prostaglandin E Receptor 1a (Subtype Ep1)

Ensembl ID : ENSTNIG00000012058
Gene Symbol: PTGER1A
2 Cross references
167 Possible Orthologues:

Prostaglandin E Receptor 2a (Subtype Ep2)

Ensembl ID : ENSTNIG00000010344
Gene Symbol: PTGER2A
2 Cross references
202 Possible Orthologues:

Prostaglandin E Receptor 3

Ensembl ID : ENSTNIG00000010497
Gene Symbol: PTGER3
2 Cross references
194 Possible Orthologues:

Prostaglandin E Receptor 4 (Subtype Ep4) A

Ensembl ID : ENSTNIG00000016684
Gene Symbol: PTGER4A
2 Cross references
202 Possible Orthologues:

Prostaglandin E Receptor 4 (Subtype Ep4) B

Ensembl ID : ENSTNIG00000007493
Gene Symbol: PTGER4B
2 Cross references
201 Possible Orthologues:

Prostaglandin I2 Receptor

Ensembl ID : ENSTNIG00000001391
Gene Symbol: PTGIR
2 Cross references
187 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSTNIG00000015589
Gene Symbol: PTGS1
2 Cross references
211 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).